- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Hereditary angioedema
- Meeting Date: July 2019
- Public Summary Document (PSD) July 2019 PBAC Meeting - (PDF 706KB)
- Public Summary Document (PSD) July 2019 PBAC Meeting - (Word 181KB)
Lanadelumab – July 2019
Lanadelumab: Solution for injection 300 mg in 2 mL; Takhzyro®
Last updated
15 November 2019